Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
Table reports the results for
2023-07-13

Table 3 reports the results for the categorical coding of diagnosis. The categorical coding is less hypothesis driven than the continuous coding because it allows for nonlinear interactions that are driven by only two groups (CN → MCI stable, CN → MCI progressor, and CN → AD). That said, this analys
-
Another issue is that the vast majority of
2023-07-13

Another issue is that the vast majority of data from PET and CSF are from selected participants recruited through tertiary care dementia centers [176]. It is widely recognized that clinic-based participants differ from community-based studies, for example, the amount, type, and distribution of neuro
-
MD was the recipient of
2023-07-13

MD was the recipient of the Intergroupe Francophone de Cancérologie Thoracique (IFCT) Alain Depierre Grant in 2014. JP was the recipient of the ARISTOT (Association de Recherche, d’Information Scientifique et Thérapeutique en Oncologie Thoracique) grant in 2016. Conflicts of interest statement
-
Lorlatinib is an orally active brain penetrant
2023-07-13

Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F
-
Decrease in soluble protein content in diabetic
2023-07-13

Decrease in soluble protein content in diabetic lenses compared with those in control lenses in present study could be due to leakage of proteins and insolubilization. T. purpurea treatment could increase the levels of soluble proteins in diabetic lenses may be by preventing cross-linking/aggregatio
-
br KYN Acts on AhR To Induce Tolerogenic
2023-07-13

KYN Acts on AhR To Induce Tolerogenic Immunity IDO1 and TDO2 are intracellular heme-containing metalloproteins that catalyze the committing and rate-limiting step of the KYN pathway (KP) that converts the essential amino Kartogenin tryptophan to a series of biologically active second metabolites
-
This study revealed that EAAT expression was increased weeks
2023-07-13

This study revealed that EAAT2 p-Cresyl sulfate was increased 4–8 weeks after cauterization as our previous work (Park et al., 2009). RGC death could not be blocked despite activation of EAAT2, which is one of glutamate transporters in cone photoreceptors and some bipolar cells, in chronic ocular h
-
br Conclusions br Acknowledgments This research was funded b
2023-07-13

Conclusions Acknowledgments This research was funded by the National Science Foundation Committee (NSFC) of China (Nos. 81171058 and 81471146) and Capital Development Scientific Research in China (Nos. 2011-5001-04 and 2014-4-5013). We are grateful for all of the participants who donated blood
-
br There is evidence to suggest that GMF activities are
2023-07-12

There is evidence to suggest that GMF activities are regulated in vivo by post-translational modification. indeed, there is strong precedent for ADF-homology family proteins being regulated in this manner. Cofilin is inhibited by phosphorylation of a serine residue at its N terminus. This residue
-
The synthetic route to M developed by Rice was
2023-07-12

The synthetic route to M100907 developed by Rice was utilized, however, the chiral resolution was carried out at an earlier stage to provide the possibility of introducing different substituents onto the piperidinyl group. The conditions for this resolution were different from previously reported.
-
Later the same group designed and
2023-07-12

Later, the same group designed and prepared several Δ16-steroidal C17 benzoazoles and pyrazines and evaluated their CYP17 and 5α-reductase inhibitory activities, binding to and transactivation of the AR, as well as their antiproliferative effects against two human PC cell lines (LNCaP and LAPC4) [18
-
Five alternatively spliced isoforms of ATX
2023-07-12

Five alternatively-spliced isoforms of ATX have been described and all are catalytically active [16], [17]. The original ATX described in 1992 is termed ATXα, whereas the most abundant isoform is ATXβ and is the same isoform responsible for plasma lysoPLD activity [18]. Full length ATX is synthesize
-
The synthesis of compounds in
2023-07-12

The synthesis of compounds in which the ethyl linker has been modified to the carbamate and urea derivatives , and is shown in . Thus the diamine was reacted with glycolic 10Panx mg to give the alcohol followed by Mitsunobu reaction with phthalimide to give . Deprotection with hydrazine gave th
-
Demonstration of in vivo efficacy of potential chemopreventi
2023-07-12

Demonstration of in vivo efficacy of potential chemopreventive agents in animal models is necessary for their clinical development. Our present study provides experimental evidence that CuB 0.1μmol by oral administration (for 2weeks before the cancer cell injection, 5days per week) significantly inh
-
br Conflict of interest statement
2023-07-12

Conflict of interest statement Acknowledgments Introduction Cellular responses to genotoxic stress in eukaryotic cells are coordinated by members of the phosphoinositide kinase related protein kinase (PIKK) family. Two members of this family, Ataxia–Telangiectasia mutated (ATM) and ATM and
15484 records 346/1033 page Previous Next First page 上5页 346347348349350 下5页 Last page